This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Kidney Cancer
ZIRCON
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Available Urotoday Newsletters - Site Registration Required
Bladder Cancer Weekly
Go
Reset
Send Date
Subject
Created Date
ID
Asc
Desc
Paradigm Shifts that Elevated Care in 2024: Looking Ahead into 2025
Sent on 02 January 2025
Receive via e-mail
Bladder Cancer Weekly
Sent on 30 December 2024
Receive via e-mail
Paradigm Shifts that Elevated GU Care in 2024: Key Breakthroughs of the Year
Sent on 26 December 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 23 December 2024
Receive via e-mail
International Bladder Cancer Group Quarterly Newsletter: Volume 3
Sent on 21 December 2024
Receive via e-mail
Managing BCG-Unresponsive NMIBC: Treatment Strategies, Progression, and Emerging Therapies
Sent on 19 December 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 16 December 2024
Receive via e-mail
Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting for Muscle-invasive Bladder Cancer
Sent on 13 December 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 09 December 2024
Receive via e-mail
SUO 2024: Setting the Stage: Our Current Options for NMIBC
Sent on 06 December 2024
Receive via e-mail
SUO 2024 Highlights: Advances in RCC, Testicular Cancer, NMIBC, and Emerging Therapies
Sent on 06 December 2024
Receive via e-mail
CG Oncology Announces Bond-003 Topline Results
Sent on 05 December 2024
Receive via e-mail
Society of Urologic Oncology (SUO) 2024: Exploring Advanced Disease, Adjuvant Therapy, and the Impact of Smoking Cessation
Sent on 05 December 2024
Receive via e-mail
Society of Urologic Oncology (SUO) 2024 Advancements in Bladder Cancer Treatment
Sent on 04 December 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 02 December 2024
Receive via e-mail
Reducing Bladder Cancer Recurrence: The Role of Improved Detection in Bladder Cancer
Sent on 30 November 2024
Receive via e-mail
New Horizons in the Treatment of Bladder Cancer
Sent on 26 November 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 25 November 2024
Receive via e-mail
Innovative Therapies in GU Cancers
Sent on 20 November 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 18 November 2024
Receive via e-mail
Occupational and Environmental Risk Factors in Bladder Cancer
Sent on 12 November 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 11 November 2024
Receive via e-mail
The Contemporary Role of Immunotherapy in Bladder Cancer
Sent on 11 November 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 04 November 2024
Receive via e-mail
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence from South Central Section AUA
Sent on 02 November 2024
Receive via e-mail
South Central Section American Urological Association on Emerging Treatments for NMIBC and Ablative Treatments for Renal Cell Carcinoma
Sent on 01 November 2024
Receive via e-mail
Bladder Preservation Strategies - A Modern Choice for Patients
Sent on 29 October 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 28 October 2024
Receive via e-mail
Harnessing Artificial Intelligence in Bladder Cancer - Digital Tools for Enhanced Diagnosis and Treatment
Sent on 23 October 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 21 October 2024
Receive via e-mail
Advances in the Treatment of Bladder Cancer
Sent on 17 October 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 14 October 2024
Receive via e-mail
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis
Sent on 09 October 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 07 October 2024
Receive via e-mail
Event-Free Survival as Surrogate Endpoint in MIBC and Bladder Cancer Treatment Breakthroughs
Sent on 07 October 2024
Receive via e-mail
ASTRO 2024: Treatments for Advanced Bladder Cancer and Small Cell GU Neuroendocrine Tumors
Sent on 02 October 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 30 September 2024
Receive via e-mail
A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer
Sent on 26 September 2024
Receive via e-mail
International Bladder Cancer Group Quarterly Newsletter: Volume 2
Sent on 24 September 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 23 September 2024
Receive via e-mail
First Data from the 2024 International Bladder Cancer Network Annual Meeting
Sent on 21 September 2024
Receive via e-mail
Highlights from the International Bladder Cancer Network 2024 Annual Meeting
Sent on 21 September 2024
Receive via e-mail
ESMO 2024: Informing Clinical Practice in Bladder Cancer and Renal Cancer
Sent on 20 September 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 16 September 2024
Receive via e-mail
ESMO 2024 Presidential Symposium II NIAGRA A Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer
Sent on 16 September 2024
Receive via e-mail
ESMO 2024 Novel Therapeutic Approaches for ARPI-Resistant Disease and Bladder Preservation Strategies
Sent on 14 September 2024
Receive via e-mail
Disparities in Bladder Cancer Detection and Treatment
Sent on 09 September 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 09 September 2024
Receive via e-mail
Bladder Cancer Weekly
Sent on 02 September 2024
Receive via e-mail
PSMA PET and Radioligand Therapy in 2024 - The Treatment Landscape in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Sent on 27 August 2024
Receive via e-mail
Page
of 11
Display #
5
10
15
20
25
30
50
100
Results 1 - 50 out of 547
Send the selected Newsletters to...
Name
E-mail
Send
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
